Solid Biosciences (SLDB) Long-Term Debt Repayments (2024 - 2025)
Quarterly results put Long-Term Debt Repayments at $203000.0 for Q4 2025, up 58.59% from a year ago — trailing twelve months through Mar 2026 was $588000.0 (down 3.29% YoY), and the annual figure for FY2025 was $723000.0, up 52.85%.
Solid Biosciences has reported Long-Term Debt Repayments over the past 2 years, most recently at $203000.0 for Q4 2025.
- Long-Term Debt Repayments reached $203000.0 in Q4 2025 per SLDB's latest filing, down from $243000.0 in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at $243000.0 in Q3 2025 and bottomed at $120000.0 in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 203,000.00 |
| Dec 31, 2025 | 203,000.00 |
| Sep 30, 2025 | 243,000.00 |
| Sep 30, 2025 | 243,000.00 |
| Jun 30, 2025 | 142,000.00 |
| Jun 30, 2025 | 142,000.00 |
| Mar 31, 2025 | 135,000.00 |
| Mar 31, 2025 | 135,000.00 |
| Dec 31, 2024 | 128,000.00 |
| Dec 31, 2024 | 128,000.00 |
| Sep 30, 2024 | 120,000.00 |
| Sep 30, 2024 | 120,000.00 |
| Jun 30, 2024 | 225,000.00 |
| Jun 30, 2024 | 225,000.00 |